Clinical trial
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
NCT00311402 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00311402 |
|---|---|
| Title | JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme |
| Official title | JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cerebrovascular Accident |
| Intervention type | Drug, Other |
| Interventions | Aggrenox capsule, Acetylsalicylic Acid (ASA) |
| Enrollment | 1,295 |
| Start date | Apr 1, 2006 |
| Primary completion | Mar 1, 2009 |
| First posted | Apr 6, 2006 |
| Last update posted | Feb 14, 2014 |
| Countries | Japan |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: